Background and Purpose: The aim of this study was to investigate the regional differences in the in vivo vasodilator responses to vasopressin, which is thought to stimulate the release of nitric oxide from the endothelium, in canine cerebral arteries by angiography.
It is generally accepted that vasopressin produces an antidiuretic effect in the kidney and induces vasocontraction in vascular smooth muscle. Recent studies, however, have demonstrated that vasopressin has a vasodilator effect on various vascular beds such as the cerebral, coronary, and pulmonary arteries, and that vasopressin decreases resistance in the large arteries in the cerebral and coronary circulation.1-5 The vasodilator activity of vasopressin appears to be mediated through the release of nitric oxide from the endothelium, while the vasoconstrictive effect of vasopressin is due to the direct stimulation of specific receptors in the smooth muscle.6 8 It has been shown in in vitro studies that the cerebral arteries from the different regions of the brain may differ in their responsiveness to vasopressin, since the proximal and distal branches of the middle cerebral artery did not show a vasodilator response to vasopressin similar to that of the basilar, posterior communicating, and brain-stem arteries. 89 The vasodilation induced by the injection of vasopressin See Editorial Comment, page 1053 into the vertebral artery has been characterized angiographically by its potent and long-lasting action on the cerebral arteries compared with that induced by substance P or acetylcholine.2 This in vivo finding makes it possible to investigate by angiography any regional differences in the sensitivity and responsivenens to nitric oxide stimulated by a vasopressin injection into the major cerebral arteries. To our knowledge there have been no reports on the in vivo heterogeneity of the responsiveness to vasoactive substances.
In this study, we have focused on the regional differences in the responsiveness to vasopressin in the major cerebral arteries centered around the circle of Willis at the base of the brain. The changes in the internal diameters of the intracranial vertebral, extracranial vertebral, anterior spinal, basilar, posterior communicating, internal carotid, and middle cerebral arteries have been compared angiographically after the intraarterial injection of vasopressin.
Materials and Methods

Animal Preparation
Our protocol followed the guidelines for the care and use of animals in the physiological sciences as approved 
Measurement of Vascular Diameter by Angiography
The internal diameter of various segments of the intracranial and extracranial arteries was determined by vertebral angiography. A catheter was inserted directly into the right vertebral artery just before the foramen of the transverse process of the cervical vertebra (C-6) at the base of the neck. Angiograms were performed using 3.0 mL of 65% iothalamate meglumine and were taken periodically at a fixed magnification after 10 pmol to 10 nmol of vasopressin, which was dissolved in 2.0 mL of physiological saline, or 2.0 mL of normal saline was infused into the vertebral artery over 5 seconds. The diameters of various segments of the major arteries were measured using a computerized image analysis system (IMAGE 1.27, Macintosh IIcx) and were compared to determine the effects of the peptides on vascular activity.210 The extracranial vertebral artery (the proximal portion before the C-1 transverse foramen), the intracranial vertebral artery (near the vertebrobasilar junction), the anterior spinal artery at the level of C-2, the middle third of the basilar artery, the posterior communicating artery, the internal carotid artery, and the middle cerebral artery (the proximal portion of the M-1 segment) were selected for this study.
The modulating effects of NG-monomethyl L-arginine (L-NMMA), which inhibits the formation of nitric oxide from L-arginine, on the vasodilation induced by vasopressin, substance P, and vasoactive intestinal peptide (VIP) were compared. Ten micromoles of L-NMMA were injected intracisternally 30 minutes before the administration of vasopressin, substance P, and VIP. This dose of L-NMMA, which almost maximally decreases the basal diameters of the major cerebral arteries, was determined empirically from a preliminary study. The solutions of substance P and VIP were injected intracisternally because they induced an obvious vasodilation only when administered from the extraluminal side. The injection of solutions into the cisterna magna was done after the withdrawal of the same amount of cerebrospinal fluid as was used for the L-NMMA, substance P, or VIP solution to maintain a constant intracranial pressure. Care was taken to keep the animals in a head-down position, which enhanced the contact of the preparations with the major arteries of the brain.
Materials
Synthetic Arg-vasopressin, substance P, and VIP were purchased from Peptide Institute Inc, Osaka, Japan. L-NMMA was obtained from Calbiochem, La Jolla, Calif. All other chemicals were reagent grade.
Statistical Analysis
All data are expressed as mean+SEM. Differences were analyzed with analysis of variance and Dunnett's test, as well as Student's t test. Values of P<.05 were considered statistically significant.
Results
The intravertebral administration of 2.0 mL of saline solution caused no appreciable change by angiography in the diameter of the major cerebral arteries. A vasopressin bolus over doses ranging from 10 pmol to 1 nmol produced a dose-dependent vasodilation. Doses higher than 1 nmol were less effective than 1 nmol in producing vasodilation; therefore, 1 nmol of vasopressin appeared to be the optimal dose for producing the maximal vasodilator effect, without affecting the systemic blood pressure (Fig 1) . A 1-nmol dose of vasopressin significantly dilated the major cerebral arteries, with the maximum dilation occurring 2 minutes after injection. At seven representative points along the major arteries, the difference in the vasodilator response to vasopressin was compared quantitatively (Fig 2) . The percent vasodilation was greatest in the internal carotid, posterior communicating, and basilar arteries and was approximately 150%. The percent vasodilation in the middle, anterior spinal, and intracranial vertebral arteries was somewhat smaller at approximately 130%, while the extracranial vertebral artery showed an increase of approximately 110%. The extracranial portion of the vertebral artery was less sensitive to vasopressin than the intracranial portion of the same artery and was significantly less sensitive than the anterior spinal artery at the same level of the cervical region (Fig 3) . This strong vasodilation at each point continued until at least 5 minutes after the injection of vasopressin (Table) .
Pretreatment with an intracisternal injection of 10 ,umol of L-NMMA for 30 minutes decreased the basal diameters of the basilar arteries (78.7+3.7% of control, n=6) and significantly inhibited the vasodilation induced by the intra-arterial injection of 1 nmol of vasopressin (Fig 4) . Substance P and VIP induced a longlasting vasodilation on angiography only when injected intracisternally. The pretreatment with 10 ,umol of L-NMMIA also inhibited the vasodilator effect of 10 nmol of substance P, but it did not suppress the effect of 1 nmol of VIP (Fig 5) .
There were no significant changes in the mean arterial blood pressure after the intracisternal injection of L-NMMA, substance P, or VIP.
Discussion
This in vivo study demonstrated that there is a regional difference in the responsiveness to vasopressin in the major cerebral arteries. The arteries composing the circle of Willis at the base of the brain appeared to be more sensitive to vasopressin than the other vessels tested. The internal carotid, posterior communicating, and basilar arteries dilated the most, followed by the middle cerebral artery and the intracranial portion of the vertebral artery. The extracranial portion of the vertebral artery, the artery in this study farthest from Angiography through the vertebral artery, which is the main artery supplying the cerebral circulation in dogs, could often reveal not only the posterior but also the anterior circulation supplied by the internal carotid artery. Since the internal carotid artery could respond to vasopressin to the same extent as the basilar and posterior communicating arteries, we assumed that enough blood flow was supplied by the vertebral artery to communicate with the anterior circulation. For a more precise evaluation, the influence of vasopressin on the anterior circulation may need to be investigated using a carotid artery. Because vasopressin was injected locally as a bolus in the vertebral artery, the concentration of vasopressin that reaches the various cerebral arteries may not be the same. However, the internal carotid artery, which is relatively far from the vertebral artery, could respond to vasopressin well. This fact indicates that a 1-nmol concentration of vasopressin is sufficient to stimulate endothelium-dependent vasodilation. The vasodilation induced by vasopressin may be the result of the release of nitric oxide from the endothelium, as has been shown in the canine basilar artery in vitro.679 The mechanical removal of the endothelium and V-1 antagonists reduced the vasodilator response to vasopressin in vitro. The relaxation in response to vasopressin was reduced in the presence of L-NMMA, an arginine analogue that inhibits the activity of nitric oxide synthase, and was restored by the addition of L-arginine but not D-arginine.9 In this study, the intracisternal injection of L-NMMA suppressed the vasodilator activities of vasopressin and substance P but not of VIP. The response to substance P, unlike that of VIP, has been found to be dependent on the presence of an intact endothelium.1" These findings support the previous in vitro evidence and suggest that the intracisternal injection of L-NMMA inhibits the synthesis of nitric oxide in the endothelium from the extraluminal side. It is likely that vasopressin decreases the resistance of the large arteries around the circle of Willis through the release of nitric oxide from the endothelium. This result may be consistent with evidence that suggests that nitric oxide predominantly contributes to the adjustment of blood flow in large vessels. 12 A recent study has shown that nitric oxide is synthesized in the nerve terminals innervating the cerebral arteries as well as in the endothelium.13 However, it seems unlikely that vasopressin from the intraluminal side diffuses through the smooth muscle wall to reach the nerve terminals and thereby modulates the release of nitric oxide from the nerve terminals. The intracisternal injection of L-NMMA, which probably suppresses the synthesis of nitric oxide in both the endothelium and nerve terminals, decreased the diameter of the basilar artery by approximately 21%. This suggests that the synthesis and release of nitric oxide in the vascular wall may contribute to the maintenance of basal vascular tonus.
Although no vasopressin-induced vasocontraction was observed in this study, it has been reported from in vitro experiments using isolated canine vascular strips that vasopressin causes a vasocontraction in more than half of the proximal parts of the middle cerebral artery. 8 In the small branches of the middle cerebral arteries, vasopressin did not produce any significant vasoactive changes. 9 In vitro experiments that involve both the intraluminal and extraluminal access of vasopressin to the arteries might induce mixed responses by stimulating the smooth muscles, endothelium, or nerve fibers in the vascular wall. The difference in responsiveness between the in vitro and our in vivo studies may be explained by the different access of vasopressin to the arteries. However, the intracisternal injection of vasopressin (extraluminal application) in a preliminary in vivo study produced only a vasodilation in the proximal part of the middle cerebral artery on angiography (data not shown). Another consideration is that the data obtained from in vivo studies are usually affected by more factors of both a systemic and local nature. For example, the nitric oxide that is released from the endothelium of major arteries and promoted by the intra-arterial or intracisternal injection of vasopressin probably dilates the smooth muscle not only near the released site but also a little farther downstream because it is carried by the bloodstream. The half-life of nitric oxide is known to be less than 10 seconds, but it may play a role in controlling the vascular tone somewhat distal to the released site.
The possible existence of vasopressin in the endothelium or nerve terminals of the blood vessels has been demonstrated by several morphological studies.14-16 Recent biochemical data have supported this possibility since vasopressin can be extracted from rat and bovine vascular tissue.'7 Interestingly, blood vessels from hypophysectomized and Brattleboro rats also contained vasopressin at levels similar to those of intact control rats. These additional lines of evidence suggest that vasopressin contributes to the regulation of the regional blood flow not only as a circulating hormone, but also as a mediator of local origin.
Editorial Comment
Arginine vasopressin is released by the neurohypophysis and has been shown to be a potent constrictor of smooth muscle in many vascular beds, including the cerebral circulation.1-3 However, several recent studies have shown that arginine vasopressin can produce relaxation of canine cerebral vascular muscle via an endothelium/nitric oxide-dependent mechanism.4 6 Since previous studies have focused on 
